Shopping Cart
- Remove All
Your shopping cart is currently empty
β-Aminoarteether (SM934 free base), an orally active derivative of Artemisinin, serves a pivotal role in the research of inflammation and autoimmune disorders, including those related to lupus diseases.

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $148 | In Stock | |
| 5 mg | $372 | In Stock | |
| 10 mg | $596 | In Stock | |
| 25 mg | $987 | In Stock | |
| 50 mg | $1,380 | In Stock | |
| 100 mg | $1,890 | In Stock | |
| 200 mg | $2,530 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $378 | In Stock |
| Description | β-Aminoarteether (SM934 free base), an orally active derivative of Artemisinin, serves a pivotal role in the research of inflammation and autoimmune disorders, including those related to lupus diseases. |
| In vitro | β-Aminoarteether (SM934; 10 μM; 24 hours) directly increases IL-10 production and reduces IL-12/23p40 production in primary peritoneal macrophages upon IFN-γ stimulation [1]. Additionally, in vitro, β-Aminoarteether (SM934) inhibits Th1 and Th17 polarization without affecting Treg differentiation [1]. |
| In vivo | Treatment with β-Aminoarteether (SM934; orally administered at doses of 1-10 mg/kg daily for 3 months) substantially slowed the advancement of glomerulonephritis and enhanced survival rates in female NZB/W F1 mice aged six and a half months [1]. Additionally, β-Aminoarteether therapy bolstered the production of IL-10 by macrophages derived from these mice [1]. This indicates a promising therapeutic potential for managing glomerulonephritis in this mouse model. |
| Synonyms | β-Aminoarteether, SM934 free base |
| Molecular Weight | 327.42 |
| Formula | C17H29NO5 |
| Cas No. | 133162-24-0 |
| Smiles | C[C@@H]1[C@]2([C@]34[C@@](O[C@](C)(OO3)CC[C@]4([C@H](C)CC2)[H])(O[C@@H]1OCCN)[H])[H] |
| Storage | Pure form: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 60 mg/mL (183.25 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (6.11 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.